Clinical Trials Browser

Carcinoma, Medullary × cemiplimab × 90 days × Clear all

NCT06444880 2026-06-04

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Phase 2 Recruiting

Sarcoma, Carcinoma, Medullary